|1.||Wolfert, Margreet A: 2 articles (02/2009 - 10/2007)|
|2.||Boons, Geert-Jan: 2 articles (02/2009 - 10/2007)|
|3.||Buskas, Therese: 2 articles (02/2009 - 10/2007)|
|4.||Ingale, Sampat: 2 articles (02/2009 - 10/2007)|
|5.||Spisani, S: 2 articles (11/2000 - 03/2000)|
|6.||Tomatis, R: 2 articles (11/2000 - 03/2000)|
|7.||Tunheim, Gro: 1 article (01/2015)|
|8.||Jonassen, Christine Monceyron: 1 article (01/2015)|
|9.||Cox, Rebecca Jane: 1 article (01/2015)|
|10.||Norwegian Pandemic Group: 1 article (01/2015)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
12/01/2013 - "Peptide T (PT), an octapeptide fragment located in the V2 region of the HIV-1 gp120-coating protein, appears to be beneficial in the treatment of psoriasis. "
11/01/1998 - "Antichemotactic activities of peptide T analogue could be a possible explanation for its therapeutic efficacy in psoriasis."
01/01/1994 - "Peptide T: a new treatment for psoriasis? "
01/01/1991 - "Peptide T a new treatment for psoriasis? "
01/01/1995 - "These changes in the distribution and density of Langerhans' cells represent their rearrangement during the course of psoriasis and/or the remission after peptide T treatment.(ABSTRACT TRUNCATED AT 250 WORDS)"
|2.||Acquired Immunodeficiency Syndrome (AIDS)
07/22/1989 - "Improvement in AIDS patients on peptide T."
11/01/1996 - "Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. "
12/01/2002 - "We now report that an intravenous bolus of peptide T normalizes nocturnal GH secretion in two out of three children with AIDS. "
11/01/1996 - "Intranasal Peptide T is safe but ineffective in the treatment of painful DSP associated with AIDS."
01/01/1991 - "Pharmacokinetics of peptide T in patients with acquired immunodeficiency syndrome (AIDS)."
|3.||HIV Infections (HIV Infection)
02/19/1993 - "These studies suggest that gp120 and gp120-derived toxic fragments may contribute to the neurological and neuropsychiatric impairment related to HIV infection, and that peptide T appears to be effective in preventing gp120-associated neurotoxicity in developing rodents."
06/01/1991 - "Study of peptide T for HIV infection."
01/01/2001 - "Peptide T can block HIV infection of human T cells. "
11/01/1996 - "To assess the safety and efficacy of Peptide T in the treatment of painful distal symmetrical polyneuropathy (DSP) associated with human immunodeficiency virus (HIV) infection. "
11/01/1993 - "Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. "
11/01/1997 - "Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T."
11/01/1997 - "This placebo-controlled, double blind, cross-over study tested the efficacy of two different doses of Peptide T in the treatment of nine intravenous drug users with early AIDS dementia who were also receiving methadone and AZT. "
|1.||Biological Markers (Surrogate Marker)
|3.||Cyclic AMP (AMP, Cyclic)
|7.||Membrane Proteins (Integral Membrane Proteins)
|9.||N-acetylmuramyl-alanylglutamine-n-butyl ester (murabutide)